Exciting News: Exothera Teams Up with Vaxthera on COVID-19 Vaccine Project 

Jumet, Belgium, January 7th 2025 — Exothera and Vaxthera Join Forces to Advance Universal COVID-19/Mpox Bivalent Vaccine Development 

Exothera, a leading end-to-end CDMO, is excited to announce a collaboration with Vaxthera to advance the development of an MVA-based universal COVID-19/Mpox bivalent vaccine. Exothera will provide process development, scale-up, and GMP manufacturing to support Vaxthera’s Phase 1 clinical trial in the EU. 

Cédric Volanti, CEO of Exothera, commented: 

“At Exothera, we are committed to accelerating the development of life-saving therapies. Partnering with Vaxthera on this innovative project allows us to make a meaningful contribution to the global health. Our expert team and state-of-the-art facilities are ready to bring this important vaccine one step closer to the patients who need it.” 

Jorge Osorio, CEO of Vaxthera, added: 

“This partnership with Exothera marks a significant milestone for Vaxthera as we work towards advancing our universal COVID-19/Mpox bivalent vaccine candidate. Together, we are taking important steps to address the ongoing challenges posed by these diseases.” 

This collaboration underscores the shared mission of Exothera and Vaxthera: harnessing innovation to develop vaccines that can improve global health outcomes. Together, we are bringing science to life. 

Stay tuned for updates on this critical project. 

About Vaxthera 

VaxThera is a Colombian private sector initiative that seeks to contribute to the health security and independence of Latin America through research, development, and state-of-the-art manufacturing of vaccines and therapeutics. We aim to promote prevention programs for neglected tropical diseases by making safe, next-generation vaccines available in Colombia, the region, and the world. These capacities will foster collaboration for pandemic preparedness and global health security. For more information:  www.vaxthera.com 

About Exothera 

Exothera is an end-to-end CDMO partner delivering pre and early clinical process development, manufacturing optimization and CMC support for viral vector and RNA therapeutics and vaccines. We assist clients from start to scale, up to commercial manufacturing, including analytical testing and regulatory consultation. Thanks to our game changing technologies and experienced team, we help bring innovative therapies from bench to patient with quality, at speed and cost-effectively. For more information, visit www.exothera.world. 

For media inquiries, please contact: 

Barbara Cornelissen, b.cornelissen@univercells.com